
Small Pharma
Pipeline of novel patent-protected deuterium-enriched tryptamine compounds for psychedelic-assisted psychotherapy as a rapid onset, sustained treatment for mental health disorders.
Get premium to view all results
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 Valuation: €0.0 | round | |
* | N/A | Acquisition | |
Total Funding | 000k |

ACF Investors(exited)

O2h Ventures(exited)

re.Mind Capital(exited)

Ambria Capital(exited)

Adrian Rands(exited)
EUR | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 |
% growth | - | 4 % | - | - |
EBITDA | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (8000 %) | (7232 %) | - | - |
Profit | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | (9061 %) | - | - |
EV | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | - | 2473 % | - | - |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.